Objective. Cryopyrin-associated periodic syndromes (CAPS) result from gain-of-function mutations in the NLRP3 gene, which causes excessive release of interleukin-1b (IL-1b) and systemic inflammation. While pathogenetic NLRP3 variant phenotypes are well-characterized, low-penetrance NLRP3 variants represent a significant clinical challenge. The aims of this study were to determine the clinical phenotype, the in vitro biologic phenotype, and the effect of anti-IL-1 treatment in patients with low-penetrance NLRP3 variants.
Cryopyrin-associated periodic syndromes (CAPS) encompasses a continuous spectrum of severity. The clinical phenotype of CAPS comprises the 3 conditions previously described as familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID; also known as chronic infantile neurologic, cutaneous, articular [CINCA] syndrome) (1) . CAPS is caused by single heterozygous germline or somatic gainof-function mutations in the NLRP3 gene that encodes the protein cryopyrin (2) . Cryopyrin nucleates an NLRP3 inflammasome, which regulates the activation and cleavage of caspase 1, which in turn, cleaves the proinflammatory cytokines interleukin-1b (IL-1b) and IL-18 (3). Other functions attributed to the NLRP3 inflammasome include NF-jB activation and pyroptotic cell death (4) . More than 90 heterozygous nonsynonymous variants in NLRP3 have been reported in patients with clinical features consistent with CAPS (see Infevers database, online at http://fmf.igh.cnrs.fr/ISSAID/infevers/). Some mutations associated with clinical phenotypes have been confirmed to be caspase 1 activating in vitro, but the majority have not been tested (5) . Most variants are not identified in unaffected family members or in genetic population databases.
Low-penetrance NLRP3 variants, including Q703K (rs35829419), R488K (rs145268073), and V198M (rs121908147), have been identified in some unaffected family members and are present at low frequencies in normal control populations, which raises questions about the functional and clinical significance of these controversial variants (1) . Accurate classification of patients with these variants has clinical relevance, as effective therapies are available. The aims of this study were as follows: to describe the clinical phenotype and laboratory findings in patients with low-penetrance NLRP3 variants, to determine the functional biologic phenotype in vitro, and to analyze the effect of treatment with IL-1 inhibitors.
PATIENTS AND METHODS
This multicenter observational study included consecutive children and adults with a clinical presentation suggestive of CAPS at the time of baseline examination and carrying 1 of the 3 most common low-penetrance NLRP3 variants: Q703K, R488K, or V198M. Seven centers participated in the study. The control group consisted of consecutive patients with pathogenetic NLRP3 mutations, including A439V, E311K, and T348M (6) . Data were acquired from structured patient interviews, then cross-referenced and enriched by chart reviews. The study was approved by the ethics committee of the University Hospital Tuebingen (no. 151/2012BO1) and of all participating centers.
Genetic testing. Standard CAPS gene mutation screening for exon 3 of the NLRP3 gene was performed in all patients. Additional immune dysregulation or autoinflammation gene testing was completed when clinically indicated, according to the discretion of the treating physician, in specific subjects, including those carrying the MEFV (the gene for familial Mediterranean fever), TNFRSF1A (the gene for tumor necrosis factor [TNF] receptor-associated periodic syndrome), and MVK (the gene for mevalonate kinase deficiency, or hyper-IgD syndrome) genes. Patients and family members were further evaluated when warranted.
Demographic and clinical characteristics, disease activity scores, and inflammatory marker levels. Demographic data included sex, age, ethnicity, and family history. Median age at the onset of symptoms, at the time of diagnosis, and at the initiation of therapy with IL-1 inhibitors was determined. CAPS phenotypes were recorded. Systemic features of inflammation, such as fever, headache, and fatigue, and CAPSspecific organ manifestations were captured. Other clinical symptoms captured included gastrointestinal symptoms, such as abdominal pain, oral ulcers, diarrhea, constipation, nausea, vomiting, and gastroesophageal reflux (GERD). Disease activity was determined using the Disease Activity Score (DAS) for MWS (7) . Gastrointestinal symptoms are not in the DAS for MWS and were therefore recorded separately. Inflammatory markers included the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum amyloid A (SAA) values. Serum cytokine biomarkers were TNF, IL-6, and S100A12.
In vitro assays of inflammasome activation. Generation of expression vectors, cell lines, caspase 1 activity by flow cytometry, caspase 1 cleavage by Western blotting, NF-jB by luciferase assay, retroviral transductions, cell death by flow cytometry, IL-1b release by enzyme-linked immunosorbent assay, and IL-1b release in whole blood stimulation assays were conducted as previously described (see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40208/ abstract).
Treatment and response to therapy with IL-1 inhibitors. IL-1 inhibitors were administered subcutaneously at the following starting doses: anakinra 100 mg/day in adults and 1-2 mg/kg/day in children, canakinumab 150 mg every 8 weeks in adults and 2 mg/kg every 8 weeks in children, and rilonacept 16 mg/week in adults and 2.2 mg/week in children. Data from the assessments performed at baseline and at the 1-year follow-up were captured for study. Treatment responses were defined as follows (8); a complete response was defined as no or minimal disease activity, as demonstrated by a DAS for MWS of ≤5, no rash and normal CRP (<0.5 mg/dl), ESR (<22 mm/hour), and SAA (<10 mg/liter) levels. A partial response was defined as a DAS for MWS of >5 but <10, and/or the presence of a mild rash and/or the elevation of 1 of the markers of inflammation. Treatment safety was monitored, and adverse effects were captured.
Statistical analysis. Demographic data, clinical findings, and laboratory findings were analyzed using descriptive statistics. * IL-1 = interleukin-1; FCAS = familial cold autoinflammatory syndrome; MWS = Muckle-Wells syndrome; NOMID = neonatal-onset multisystem inflammatory disease; CINCA = chronic infantile neurologic, cutaneous, articular syndrome; DAS = Disease Activity Score (range of possible scores 0-20); GERD = gastroesophageal reflux disease; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; SAA = serum amyloid A; TNF = tumor necrosis factor. † P < 0.05 versus the group with known pathogenetic NLRP3 variants.
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testing and graphing for functional assays were performed with GraphPad Prism 5 software using one-way analysis of variance. Flow cytometry data were analyzed using FlowJo software.
RESULTS
Patients and genetics. The study included 45 patients (38 families) with NLRP3 low-penetrance variants. Twenty-four (53%) were male and 21 (47%) were female. A total of 26 (58%) were children ages 0.4-18 years. The median age at symptom onset in the NLRP3 low-penetrance variants cohort was 9.1 years (range 0-45 years). All but 1 patient was Caucasian. NLRP3 lowpenetrance variants identified were Q703K in 19 (42%), V198M in 20 (44%), and R488K in 6 patients (13%). The frequency of these variants in the Exome Aggregation Consortium gene database (available at http://exac. broadinstitute.org; accessed August 2016), which includes >60,000 individuals, was 0.04095 for Q703K, 0.00826 for V198M, and 0.00059 for R488K.
Additional autoinflammatory gene variants were detected in 4 female patients with the Q703K variant and 1 male patient with V198M. Of the 4 female patients with Q703K, 1 had an additional NLRP3 variant of unknown significance (E627G); she had typical CAPS symptoms, including fever and cold-induced rash. Her symptoms occurred intermittently. The second patient was found to have the additional low-penetrance R92Q variant within the TNFRSF1A gene. She had an overlapping autoinflammatory phenotype with strong CAPS features, including fever, cold-induced rash, headache, and papilledema. Her twin sister had the identical 2 low-penetrance variants; her autoinflammatory phenotype was less pronounced. The fourth patient had an additional pathogenetic V726A variant within the MEFV gene; she presented with a severe autoinflammatory phenotype with strong CAPS features. Symptoms occurred monthly, lasting an average of 3 days. In the male patient with the NLRP3 low-penetrance V198M variant, the common MEFV gene variants E148Q, P369S, and R408Q were identified. He presented with a severe autoinflammatory phenotype with twice monthly attacks that lasted an average of 5 days.
Four patients with the Q703K variant presented with symptoms of periodic fever, aphthosis, pharyngitis, and adenitis syndrome in addition to features of CAPS. The control group included 28 patients with pathogenetic NLRP3 variants: A439V in 13, E311K in 12, and T348M in 3 ( (Table 1) .
Overall, fatigue was the most common systemic feature, being present in 78% of the patients with lowpenetrance NLRP3 variants versus 82% of those with pathogenetic NLRP3 variants. Fever was more frequently reported in the low-penetrance group (76% versus 18%; P < 0.001). However, other CAPS-associated organ manifestations, including eye involvement (89% versus 56%; P = 0.003) such as conjunctivitis (86% versus 44%; P < 0.001) and uveitis (25% versus 0%), sensorineural hearing loss (79% versus 18%; P = 0.001), arthritis (43% versus 18%; P = 0.02) and renal involvement (61% versus 31%; P = 0.01), were more commonly seen in patients with pathogenetic NLRP3 variants compared to those with low-penetrance NLRP3 variants. Both groups reported similar frequencies of headache, rash, myalgia, and arthralgia. Gastrointestinal symptoms, including abdominal pain (56% versus 25%; P = 0.01), diarrhea (18% versus 0%), constipation (24% versus 0%), nausea (20% versus 0%), vomiting (31% versus 0%) and GERD (22% versus 0%) (P < 0.05 for each of these comparisons), were more commonly reported in patients with low-penetrance NLRP3 variants ( Table 2 ). The median DAS for MWS was 10 in both groups (Table 1) .
Laboratory findings. Patients with pathogenetic NLRP3 variants more commonly had abnormal CRP and SAA levels as compared to those with low-penetrance NLRP3 variants (75% versus 34% for CRP and 80% versus 36% for SAA; P < 0.05 for each comparison). In contrast, levels of the serum cytokines TNF and S100A12 were higher in the small subset of patients with low-penetrance NLRP3 variants tested compared to the controls. In 7 patients with elevated S100A12 values, CRP was normal (Table 1) .
Functional impact of low-penetrance NLRP3 variants. Caspase 1 activity and cleavage. Cells expressing the low-penetrance NLRP3 variants showed mildly increased caspase 1 activity (THP-1 cells) and cleavage (HEK 293 cells) over wild-type (WT) NLRP3, with none of the variants (V198M, R488K, and Q703K) reaching statistical significance. Overall, these levels were markedly lower than those for the known CAPS mutations (the L353P FCAS mutation, the L264F NOMID mutation), suggesting an intermediate functional phenotype for all low-penetrance variants ( Figures 1A-C) .
IL-1b release. Figure 1D ). Cell death and NF-jB activation. Another caspase 1-mediated function is a cell death process commonly known as pyroptosis, which was significantly elevated in THP-1 cells transfected with 1 pathogenetic mutation (L264F) as compared to WT, but was only mildly raised in cells transfected with the low-penetrance NLRP3 variants and the other pathogenetic mutation ( Figure 1E ). Finally, NLRP3 has been shown to mediate caspase 1-independent activation of NF-jB. The severe pathogenetic mutation (L264F) demonstrated increased NF-jB activity. Similar results were observed for the Q703K variant, but this did not reach statistical significance ( Figure 1F) . No increase was noted in the cells transfected with the other variants or with the milder pathogenetic mutation.
IL-1b release after whole blood stimulation. Leukocytes from CAPS patients with pathogenetic variants are hyperresponsive to the innate immune stimulant lipopolysaccharide (LPS), releasing IL-1b even in the absence of ATP, the second NLRP3 inflammasome signal necessary for WT leukocytes. This functional ex vivo CAPS phenotype was not observed when testing peripheral blood from 4 patients with the low-penetrance V198M variant, suggesting that these cells are functionally similar to WT ( Figure 1G ).
Response to therapy with IL-1 inhibitors. A total of 30 consecutive patients with low-penetrance NLRP3 variants (67%) were treated with IL-1 inhibitors. Treatment response at 1 year was available in 20 (67%), half of whom were children. Three of the 10 patients without 1-year follow-up data had received treatment for <1 year. The remaining 7 patients were not seen for their annual assessment and reevaluation at their autoinflammatory center.
Of the 20 patients with 1-year follow-up data, 8 (40%) were male and 12 (60%) were female. Canakinumab was given to 5 patients with Q703K and 5 with V198M. Anakinra therapy was initiated in 6 patients with V198M, 2 with Q703K, and 1 with R488K variants. Rilonacept was used in 1 patient with the V198M variant. Ten of these 20 patients (50%) achieved complete response, with 7 (70%)-all of whom were children-requiring several dose adjustments. Ten patients (50%) had partial responses; 3 of whom were children. Five of these 10 patients (50%) were treated with a starting dose of IL-1 inhibitors with no subsequent dose adjustment.
IL-1 inhibition was effective in reducing systemic symptoms, including fever (65% versus 15%; P = 0.002), fatigue (90% versus 35%; P = 0.001), arthralgia (85% versus 30%; P = 0.001), rash (75% versus 35%; P = 0.04), and conjunctivitis (40% versus 5%; P = 0.02). In contrast, oral ulcers (40% versus 20%; P = 0.13) and abdominal pain (50% versus 30%; P = 0.13) were less responsive. Overall, 10 patients (50%) had significant gastrointestinal symptoms at baseline. At 1 year, 4 of the 10 complete responders and 7 of the 10 partial responders had persistent severe gastrointestinal symptoms despite treatment with IL-1 inhibitors. Hearing loss did not improve with IL-1 inhibition in any of the affected patients. Levels of the markers of inflammation normalized in 2 of the 7 patients who had elevated levels at baseline (Table 2) .
Safety. Adverse events were documented in 8 patients. Three anakinra-treated patients developed injection site reactions, 1 of whom also reported 
DISCUSSION
This study systematically analyzed the clinical and functional impact of low-penetrance NLRP3 variants. These variants present a significant clinical challenge, as they may also be found in asymptomatic healthy individuals (1). The study results suggest a distinct clinical phenotype identified in 45 symptomatic children and adults with the low-penetrance NLRP3 variants Q703K, R488K, and V198M, which included fever and severe gastrointestinal symptoms. Importantly, the identified clinical phenotype appeared to be partnered with an intermediate activation level within the inflammasome pathways. Treatment response to IL-1 inhibition was encouraging, with half of the patients who were treated and followed up achieving a complete response at 1 year. Of these, 60% required increased dosages to achieve response. Gastrointestinal symptoms, which are currently not included in the standard CAPS outcome measures, were frequently treatment-refractory and persisted in more than half of the children and adults who were reevaluated at the 1-year follow-up.
Symptomatic children and adults with low-penetrance NLRP3 variants display a distinct clinical phenotype, which includes typical CAPS symptoms of headache, urticaria-like rash, and arthralgia as well as atypical CAPS symptoms of severe gastrointestinal symptoms. Studies have reported an association of NLRP3 and susceptibility to inflammatory bowel disease (9) , which is further supported by studies of NLRP3-knockout mice (10) . Patients with low-penetrance NLRP3 variants displayed an intermediate biologic phenotype, with traditional markers of inflammation being significantly less frequently elevated. Functional testing of transfected cell lines and whole blood from patients with low-penetrance NLRP3 variants showed an intermediate functional activation within the NLRP3 inflammasome pathways of cell death, NF-jB activation, caspase 1 activity and cleavage, and IL-1b release. Levels were found to be higher than the wild-type but lower than one or both of the typical disease-causing variants (L353P, L264F). These findings support those of a previous study, in which THP-1 cells retrovirally transduced with Q703K also showed an intermediate activation (11) .
IL-1b secretion was decreased in cells from patients with low-penetrance NLRP3 variants as compared to confirmed pathogenetic CAPS mutations (12) . Interestingly, the Q703K variant resulted in increased NF-jB activation that was comparable to the activation seen in the severe pathogenetic variant, but was not statistically significant (11) . These results in conjunction with high levels of TNF may indicate the presence of an additional inflammatory pathway that may be responsible for the distinct disease manifestations in some patients with low-penetrance NLRP3 variants.
Overall, IL-1 inhibitors were found to be effective in symptomatic children and adults with low-penetrance NLRP3 variants. In this study, two-thirds of the patients received IL-1 inhibitors. Follow-up data at 1 year documented that all 20 patients responded; half of them achieved complete response and half achieved partial response.
These results support recent reports of patients with low-penetrance variants treated effectively with IL-1 inhibitors (12) . Similar to known pathogenetic NLRP3 variants, children had a higher likelihood of complete response (70% versus 30%) (13, 14) . The long-term efficacy study of canakinumab in CAPS demonstrated a response rate of 83% (90 of 109) (13) . IL-1 inhibition was effective in treating the systemic features of fever, fatigue, arthralgia, rash, and conjunctivitis. Gastrointestinal symptoms improved, but persisted despite dosage increases in many patients. Dosage adjustment increased the likelihood of achieving complete response, the treatto-target concept recently proposed for known pathogenetic NLRP3 variants (14) .
There are several limitations to the study. It included a small cohort with unequal representation of low-penetrance variants. However, the study included consecutive symptomatic children and adults at large centers for autoinflammatory diseases and characterized clinical and biologic phenotype and response to therapy using standardized instruments. The reported in vitro studies may not reflect in vivo mechanisms that result in disease manifestations. However, the in vitro functional analysis of the 3 different low-penetrance NLRP3 variants compared to pathogenetic variants may allow for further hypothesis generation when attempting to understand the functional basis and clinical impact. Finally, whole-exome sequencing to detect further mutations and deep sequencing for somatic mutations was not performed (15) . Treatment outcome data were available in only 10 of the 20 patients who received IL-1 inhibition. This may have resulted in a possible overestimation of the treatment effect.
Symptomatic children and adults with low-penetrance NLRP3 variants present with a distinct clinical phenotype, which may include atypical CAPS features such as severe gastrointestinal symptoms partnered with typical systemic CAPS features and milder organ manifestations such as rash, conjunctivitis, and arthralgia. Functional studies of these variants suggest an intermediate biologic phenotype, yet patient-derived leukocytes lack the "hyperresponsive CAPS phenotype" in response to the innate immune stimulant LPS. Clinically, IL-1 inhibition was effective; however, severe gastrointestinal symptoms were the least responsive, even to higher doses of anti-IL-1 drugs. Additional research is needed to better understand the biologic basis of these symptoms and target them accordingly.
